KROS
Keros Therapeutics, Inc.$10.19+0.14 (+1.39%)Prev Close$10.05·MCap$329.6M·P/E4.44·Vol111.2K·Yield—
▲
Buys (12M)
3
$44.7K
▼
Sells (12M)
9
$181.05M
◆
Net Activity
Net Seller
$181.01M
●
Active Insiders
10
last 12 mo
Over the past 12 months, insider activity at Keros Therapeutics, Inc. (KROS) has been dominated by selling, with 3 insider purchases totaling $44.7K and 9 insider sales totaling $181.05M. The most recent insider transaction was by Farzan Nima (director), who sold $28.2K worth of shares on Jun 8, 2026. Keros Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $329.6M.
KROS Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | Farzan Nima | director | Sell | 2,625 | $10.73 | $28.2K | 9,767 |
| Jun 8, 2026 | Knowles Julius | director | Sell | 2,625 | $10.73 | $28.2K | 10,958 |
| Jun 5, 2026 | Seth Alpna | director | Sell | 2,625 | $10.72 | $28.1K | 9,767 |
| May 19, 2026 | BIENAIME JEAN JACQUES | director | Buy | 1,000 | $10.58 | $10.6K | 9,450 |
| Apr 17, 2026 | BIENAIME JEAN JACQUES | director | Buy | 1,000 | $11.70 | $11.7K | 8,450 |
| Mar 11, 2026 | BIENAIME JEAN JACQUES | director | Buy | 2,000 | $11.21 | $22.4K | 7,450+37% |
| Feb 19, 2026 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | Sell | 7,015 | $16.17 | $113.4K | 0 |
| Feb 18, 2026 | Cho Esther | SVP, General Counsel | Sell | 4,745 | $16.35 | $77.6K | 0 |
| Feb 18, 2026 | Lerner Lorena Raquel | Chief Science Officer | Sell | 3,873 | $16.35 | $63.3K | 0 |
| Feb 18, 2026 | Regnante Keith | CHIEF FINANCIAL OFFICER | Sell | 4,739 | $16.35 | $77.5K | 0 |
| Oct 17, 2025 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | Sell | 4,787,331 | $17.75 | $84.98M12.9% OS | 0Exit |
| Oct 15, 2025 | ADAR1 Capital Management, LLC | 10% Owner | Sell | 5,389,264 | $17.75 | $95.66M14.5% OS | 0Exit |
| Apr 11, 2025 | ADAR1 Capital Management, LLC | 10% Owner | Buy | 934,258 | $10.13 | $9.46M2.5% OS | 4,392,737+27% |
| Aug 15, 2024 | GORDON CARL L | Director | Sell | 250,000 | $44.01 | $11.00M0.7% OS | 899,212 |
| Jan 8, 2024 | Regnante Keith | Chief Financial Officer | Sell | 40,000 | $45.29 | $1.81M | 0Exit |
| Jun 12, 2023 | Regnante Keith | Chief Financial Officer | Sell | 40,000 | $46.61 | $1.86M | 4,007-91% |
| Jul 19, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 46,034 | $30.00 | $1.38M | 95,100-33% |
| Jul 15, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 1,916 | $30.00 | $57.5K | 95,100 |
| May 13, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 5,300 | $41.90 | $222.1K | 87,602 |
| Apr 13, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 5,300 | $62.77 | $332.7K | 89,583 |
| Apr 8, 2022 | Rovaldi Christopher | Chief Operating Officer | Sell | 1,728 | $65.00 | $112.3K | 0Exit |
| Apr 6, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 7,950 | $60.00 | $477.0K | 85,700 |
| Apr 5, 2022 | Rovaldi Christopher | Chief Operating Officer | Sell | 864 | $57.49 | $49.7K | 862-50% |
| Mar 15, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $53.38 | $141.4K | 87,288 |
| Feb 15, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $52.06 | $138.0K | 87,277 |
| Jan 13, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $53.75 | $142.4K | 88,030 |
| Jan 7, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $60.00 | $159.0K | 85,700 |
| Jan 5, 2022 | Knowles Julius | Director | Sell | 47,651 | $57.84 | $2.76M | 366,738 |
| Dec 15, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $50.40 | $133.6K | 86,097 |
| Dec 3, 2021 | Knowles Julius | Director | Sell | 47,651 | $54.09 | $2.58M | 395,014 |
| Nov 12, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 21,200 | $59.91 | $1.27M | 90,261 |
| Nov 5, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 10,600 | $50.00 | $530.0K | 85,700 |
| Nov 3, 2021 | Knowles Julius | Director | Sell | 47,651 | $42.12 | $2.01M | 421,041 |
| Oct 21, 2021 | Knowles Julius | Director | Sell | 8,598 | $38.20 | $328.4K | 431,273 |
| Oct 18, 2021 | Knowles Julius | Director | Sell | 26,367 | $38.56 | $1.02M | 446,608 |
| Oct 5, 2021 | Knowles Julius | Director | Sell | 12,686 | $40.10 | $508.8K | 453,112 |
| Sep 29, 2021 | Knowles Julius | Director | Sell | 95,302 | $41.17 | $3.92M | 487,249 |
| Jul 6, 2021 | Knowles Julius | Director | Sell | 47,652 | $41.31 | $1.97M | 530,196 |
| Jun 15, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $50.98 | $135.1K | 79,024 |
| Jun 15, 2021 | Ordonez Claudia | Chief Medical Officer | Sell | 1,000 | $50.99 | $51.0K | 347-74% |
| Jun 8, 2021 | Knowles Julius | Director | Sell | 19,415 | $49.07 | $952.6K | 552,227 |
| Jun 3, 2021 | Knowles Julius | Director | Sell | 28,236 | $49.71 | $1.40M | 569,996 |
| May 13, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $50.00 | $132.5K | 71,187 |
| May 13, 2021 | Ordonez Claudia | Chief Medical Officer | Sell | 1,000 | $50.15 | $50.1K | 0Exit |
| May 5, 2021 | Knowles Julius | Director | Sell | 47,651 | $57.27 | $2.73M | 595,763 |
| Apr 14, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 5,300 | $60.00 | $318.0K | 75,489 |
| Apr 14, 2021 | Ordonez Claudia | Chief Medical Officer | Sell | 1,000 | $59.93 | $59.9K | 600-63% |
| Apr 8, 2021 | Knowles Julius | Director | Sell | 9,298 | $58.81 | $546.8K | 604,885 |
| Apr 5, 2021 | Knowles Julius | Director | Sell | 38,353 | $59.72 | $2.29M | 626,197 |
| Mar 15, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 5,300 | $64.48 | $341.8K | 64,752 |
Showing 1–50 of 53
1 / 2
KROS Insider Buying Activity
The following table shows recent insider purchases of Keros Therapeutics, Inc. (KROS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 19, 2026 | BIENAIME JEAN JACQUES | director | Buy | 1,000 | $10.58 | $10.6K | 9,450 |
| Apr 17, 2026 | BIENAIME JEAN JACQUES | director | Buy | 1,000 | $11.70 | $11.7K | 8,450 |
| Mar 11, 2026 | BIENAIME JEAN JACQUES | director | Buy | 2,000 | $11.21 | $22.4K | 7,450+37% |
| Apr 11, 2025 | ADAR1 Capital Management, LLC | 10% Owner | Buy | 934,258 | $10.13 | $9.46M2.5% OS | 4,392,737+27% |
KROS Insider Selling Activity
The following table shows recent insider sales of Keros Therapeutics, Inc. (KROS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | Farzan Nima | director | Sell | 2,625 | $10.73 | $28.2K | 9,767 |
| Jun 8, 2026 | Knowles Julius | director | Sell | 2,625 | $10.73 | $28.2K | 10,958 |
| Jun 5, 2026 | Seth Alpna | director | Sell | 2,625 | $10.72 | $28.1K | 9,767 |
| Feb 19, 2026 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | Sell | 7,015 | $16.17 | $113.4K | 0 |
| Feb 18, 2026 | Cho Esther | SVP, General Counsel | Sell | 4,745 | $16.35 | $77.6K | 0 |
| Feb 18, 2026 | Lerner Lorena Raquel | Chief Science Officer | Sell | 3,873 | $16.35 | $63.3K | 0 |
| Feb 18, 2026 | Regnante Keith | CHIEF FINANCIAL OFFICER | Sell | 4,739 | $16.35 | $77.5K | 0 |
| Oct 17, 2025 | Pontifax Management 4 G.P. (2015) Ltd. | 10% Owner | Sell | 4,787,331 | $17.75 | $84.98M12.9% OS | 0Exit |
| Oct 15, 2025 | ADAR1 Capital Management, LLC | 10% Owner | Sell | 5,389,264 | $17.75 | $95.66M14.5% OS | 0Exit |
| Aug 15, 2024 | GORDON CARL L | Director | Sell | 250,000 | $44.01 | $11.00M0.7% OS | 899,212 |
| Jan 8, 2024 | Regnante Keith | Chief Financial Officer | Sell | 40,000 | $45.29 | $1.81M | 0Exit |
| Jun 12, 2023 | Regnante Keith | Chief Financial Officer | Sell | 40,000 | $46.61 | $1.86M | 4,007-91% |
| Jul 19, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 46,034 | $30.00 | $1.38M | 95,100-33% |
| Jul 15, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 1,916 | $30.00 | $57.5K | 95,100 |
| May 13, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 5,300 | $41.90 | $222.1K | 87,602 |
| Apr 13, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 5,300 | $62.77 | $332.7K | 89,583 |
| Apr 8, 2022 | Rovaldi Christopher | Chief Operating Officer | Sell | 1,728 | $65.00 | $112.3K | 0Exit |
| Apr 6, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 7,950 | $60.00 | $477.0K | 85,700 |
| Apr 5, 2022 | Rovaldi Christopher | Chief Operating Officer | Sell | 864 | $57.49 | $49.7K | 862-50% |
| Mar 15, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $53.38 | $141.4K | 87,288 |
| Feb 15, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $52.06 | $138.0K | 87,277 |
| Jan 13, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $53.75 | $142.4K | 88,030 |
| Jan 7, 2022 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $60.00 | $159.0K | 85,700 |
| Jan 5, 2022 | Knowles Julius | Director | Sell | 47,651 | $57.84 | $2.76M | 366,738 |
| Dec 15, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $50.40 | $133.6K | 86,097 |
| Dec 3, 2021 | Knowles Julius | Director | Sell | 47,651 | $54.09 | $2.58M | 395,014 |
| Nov 12, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 21,200 | $59.91 | $1.27M | 90,261 |
| Nov 5, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 10,600 | $50.00 | $530.0K | 85,700 |
| Nov 3, 2021 | Knowles Julius | Director | Sell | 47,651 | $42.12 | $2.01M | 421,041 |
| Oct 21, 2021 | Knowles Julius | Director | Sell | 8,598 | $38.20 | $328.4K | 431,273 |
| Oct 18, 2021 | Knowles Julius | Director | Sell | 26,367 | $38.56 | $1.02M | 446,608 |
| Oct 5, 2021 | Knowles Julius | Director | Sell | 12,686 | $40.10 | $508.8K | 453,112 |
| Sep 29, 2021 | Knowles Julius | Director | Sell | 95,302 | $41.17 | $3.92M | 487,249 |
| Jul 6, 2021 | Knowles Julius | Director | Sell | 47,652 | $41.31 | $1.97M | 530,196 |
| Jun 15, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $50.98 | $135.1K | 79,024 |
| Jun 15, 2021 | Ordonez Claudia | Chief Medical Officer | Sell | 1,000 | $50.99 | $51.0K | 347-74% |
| Jun 8, 2021 | Knowles Julius | Director | Sell | 19,415 | $49.07 | $952.6K | 552,227 |
| Jun 3, 2021 | Knowles Julius | Director | Sell | 28,236 | $49.71 | $1.40M | 569,996 |
| May 13, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 2,650 | $50.00 | $132.5K | 71,187 |
| May 13, 2021 | Ordonez Claudia | Chief Medical Officer | Sell | 1,000 | $50.15 | $50.1K | 0Exit |
| May 5, 2021 | Knowles Julius | Director | Sell | 47,651 | $57.27 | $2.73M | 595,763 |
| Apr 14, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 5,300 | $60.00 | $318.0K | 75,489 |
| Apr 14, 2021 | Ordonez Claudia | Chief Medical Officer | Sell | 1,000 | $59.93 | $59.9K | 600-63% |
| Apr 8, 2021 | Knowles Julius | Director | Sell | 9,298 | $58.81 | $546.8K | 604,885 |
| Apr 5, 2021 | Knowles Julius | Director | Sell | 38,353 | $59.72 | $2.29M | 626,197 |
| Mar 15, 2021 | Lachey Jennifer | Chief Scientific Officer | Sell | 5,300 | $64.48 | $341.8K | 64,752 |
KROS Insiders
Similar Stocks to KROS
VRTX
Vertex Pharmaceuticals Incorporated
$445.21+0.04%
$113.41B
REGN
Regeneron Pharmaceuticals, Inc.
$614.20+0.45%
$65.47B
ALNY
Alnylam Pharmaceuticals, Inc.
$283.35-2.09%
$40.46B
RVMD
Revolution Medicines, Inc.
$153.65+2.96%
$31.73B
UTHR
United Therapeutics Corporation
$542.43-0.54%
$23.12B
INSM
Insmed Incorporated
$98.28+1.64%
$20.41B
INCY
Incyte Corporation
$108.85+0.95%
$20.11B
MRNA
Moderna, Inc.
$50.18+1.06%
$18.89B